Table 2 Pharmacokinetic properties of A-1467729 and A-1592668.

From: A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies

 

Selected rat PK parameters

 

1 mg/kg IV

1 mg/kg PO

 

CLp (L/h/kg)

Vss (L/kg)

AUC (ng*h/ml)

F (%)

A-1467729

2.1

19.6

181.3

37

A-1592668

0.63

2.7

452

28

  1. Rats (n = 3) were dosed with A-1467729 and A-1592668 at 1 mg/kg IV or PO and clearance (CLp), volume of distribution at steady state (Vss), plasma concentration (area under the curve; AUC), and bioavailability (%F) determined (See Supplementary Materials and Methods)
Back to article page